Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr9.95 SEK
Change Today +0.20 / 2.05%
Volume 57.4K
As of 11:30 AM 08/27/15 All times are local (Market data is delayed by at least 15 minutes).

active biotech ab (ACTI) Snapshot

Open
kr9.75
Previous Close
kr9.75
Day High
kr10.05
Day Low
kr9.75
52 Week High
09/2/14 - kr32.57
52 Week Low
06/5/15 - kr8.45
Market Cap
894.6M
Average Volume 10 Days
77.7K
EPS TTM
kr-2.88
Shares Outstanding
89.9M
EX-Date
02/15/01
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ACTIVE BIOTECH AB (ACTI)

Related News

No related news articles were found.

active biotech ab (ACTI) Related Businessweek News

No Related Businessweek News Found

active biotech ab (ACTI) Details

Active Biotech AB (publ) develops drugs for the treatment of neurodegenerative diseases and cancer. The company has two projects in clinical development, such as laquinimod and tasquinimod. The Laquinimod project is a novel immunomodulatory compound for the treatment of neurodegenerative diseases; and the Tasquinimod project is an immunomodulatory, anti-metastatic substance for the treatment of prostate cancer. The company is also developing Paquinimod, an oral immunomodulatory compound for the treatment of systemic sclerosis; and RhuDex, an orally active compound for the treatment of autoimmune diseases. Its preclinical project product is ISI–Inhibition of S100 Interactions for producing patentable chemical compounds that interact with one of the quinoline compounds’ target molecules. Active Biotech AB (publ) is headquartered in Lund, Sweden.

56 Employees
Last Reported Date: 08/7/15

active biotech ab (ACTI) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: kr5.0M
Compensation as of Fiscal Year 2013.

active biotech ab (ACTI) Key Developments

Active Biotech AB Announces Consolidated and Parent Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Active Biotech AB announced consolidated and parent earnings results for the second quarter and six months ended June 30, 2015. For the quarter, on consolidated basis, Net sales were SEK 3.2 million against SEK 2.7 million a year ago. Operating loss was SEK 70.1 million against SEK 57.9 million a year ago. Loss before tax was SEK 71.9 million against SEK 58.2 million a year ago. Loss for the period was SEK 71.4 million against SEK 57.7 million a year ago. Loss per share was SEK 0.79 against SEK 0.77 a year ago. For the six months, on consolidated basis, Net sales were SEK 6.1 million against SEK 4.9 million a year ago. Operating loss was SEK 127.5 million against SEK 117.2 million a year ago. Loss for the period was SEK 129.3 million against SEK 117.9 million a year ago. Loss per share was SEK 1.44 against SEK 1.57 a year ago. Cash used in operating activities accounted for SEK 138.3 million against SEK 149.7 million a year ago. Loss before tax was SEK 130.4 million against SEK 119.0 million a year ago. For the quarter, on parent basis, net sales amounted to SEK 6.1 million against SEK 4.6 million a year ago. Operating loss was SEK 75.8 million against SEK 63.8 million a year ago. Net loss for the period was SEK 75.9 million against SEK 62.4 million a year ago. For the six months, on parent basis, net sales amounted to SEK 11.1 million against SEK 9.6 million a year ago. Operating loss was SEK 138.7 million against SEK 128.3 million a year ago. Net loss for the period was SEK 138.2 million against SEK 126.3 million a year ago.

Teva Pharmaceutical Industries Limited and Active Biotech Announce the Completion of Patient Enrollment in Laquinimod Phase III CONCERTO Trial

Teva Pharmaceutical Industries Ltd. and Active Biotech announced that the patient enrollment for the pivotal Phase III CONCERTO trial has been finalized, as well as a planned sample size re-assessment analysis of the study. CONCERTO, the third Phase III trial of laquinimod in patients with relapsing-remitting multiple sclerosis (RRMS), is designed to evaluate the safety and efficacy of laquinimod (0.6mg or 1.2mg/day) with a primary endpoint of time to Confirmed Disability Progression (CDP), as measured by the Expanded Disability Status Scale (EDSS). The sample size reassessment was included as part of the protocol to confirm that the original assumptions are in line with the study and that the sample size is adequate. Based on recent agreement with FDA, under a Special Protocol Assessment (SPA) agreement, study completion will occur when either 260 events are reached or all patients complete 24 months of study treatment (whichever occurs first). CONCERTO study results are expected to be available toward mid-2017.

Active Biotech Announces Redundancies of 47 of its Employees

Active Biotech announced that the company has made a notification of planned redundancies of 47 of its employees, which means a significant down-sizing of the operations. A notification of planned redundancies has been submitted to the local authorities ("Arbetsförmedlingen") for 47 employees out of 56. Active Biotech has also called for negotiations with the trade unions and contacts have been established with organizations such as the Swedish Employment Security Council regarding various support measures for the employees. The planned organizational change is estimated to be fully implemented as of 1 January, 2016. Active Biotech's planned organizational adjustment leads to substantially reduced operating costs. The operating costs are expected to decrease to approximately SEK 50 Million per year, from 2016.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACTI:SS kr9.95 SEK +0.20

ACTI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ACTI.
View Industry Companies
 

Industry Analysis

ACTI

Industry Average

Valuation ACTI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 73.7x
Price/Book 3.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 38.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACTIVE BIOTECH AB, please visit www.activebiotech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.